Investigational drug · Phase 2
TQB3617
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Myelofibrosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Dec 8, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "TQB3617"
First trial start
2023
Dec 12, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TQB3617", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myelofibrosis
Approved drugs for the same conditions: Myelofibrosis · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "TQB3617" as an intervention, largest first.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06122831 · 92 participants (planned) · Start Dec 12, 2023 · Primary completion Dec 2026
Drug: TQ05105 Tablets; TQB3617 Capsules · For: Myelofibrosis
Sites: Guangzhou, China; Nanning, China; Cangzhou, China · 22 sites in all
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05110807 · 38 participants (planned) · Start Jan 5, 2022 · Primary completion Oct 2022
Drug: TQB3617 · For: Advanced Malignant Tumors
Sites: Guangzhou, China; Hangzhou, China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05834543 · 34 participants · Start May 26, 2023 · Primary completion Oct 23, 2024
Drug: TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin; Penpulimab injection, Paclitaxel, Cisplatin and 1 more · For: Advanced Esophageal Squamous Cell Carcinoma
Sites: Tongling, China; Wuhu, China; Anyang, China · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- BETting on the future: BET inhibition for patients with lymphoma.
Voorhees TJ, Coombs CC · Med 2026
- TQB3617, a bromodomain and extra-terminal inhibitor, in patients with relapsed or refractory lymphoma: A multicenter, phase 1 trial.
Zhang Y, Yin Q, Zhao B, et al. · Med 2026
Also in development for Myelofibrosis
- ElriterceptTAK-226, KER-050Phase 36 trials
Takeda · Myelodysplastic Syndromes, Myelofibrosis, Anemia
- BomedemstatMK-3543, IMG-7289Phase 35 trials
Merck & Co. · Polycythemia Vera, Essential Thrombocythemia, Thrombocythemia, Essential
- RovadicitinibTQ05105Phase 35 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chronic Graft Versus Host Disease, Myelofibrosis, Graft-versus-host Disease
- KRT-232NavtemadlinPhase 34 trials
Kartos Therapeutics, Inc. · Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
- PelabresibDAK539, CPI-0610Phase 34 trials
Novartis · Myelofibrosis, Primary Myelofibrosis, Primary Myelofibrosis (PMF)
- BMS-986158Phase 22 trials
Bristol Myers Squibb · Myelofibrosis, Multiple Myeloma
- DISC-0974Phase 22 trials
Disc Medicine, Inc · Anemia, Inflammatory Bowel Disease (IBD), Inflammatory Bowel Disease (IBD); Anemia
- amsulostatPXS-5505Phase 21 trial
Syntara · Myelofibrosis, Primary Myelofibrosis (PMF), Post- Essential Thrombocythemia Myelofibrosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.